COMMUNIQUÉS West-GlobeNewswire

Peptides Canada Reports Growing Research Demand for Retatrutide Amid Expansion of Domestic Peptide Supply Market
07/09/2026
Vancouver, BC, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Peptides Canada, a domestic supplier of research-grade peptide compounds, today highlighted continued growth in demand for metabolic research peptides, including [...]
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
07/09/2026
Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
07/09/2026
Data highlights The STEP Young phase 3 trial met its primary endpoint, demonstrating greater body mass index (BMI) reduction in children aged 6 to under 12 treated with once-weekly subcutaneous semaglutide compared with [...]
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
07/09/2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress [...]
Novo Nordisk A/S - share repurchase programme
07/09/2026
Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/09/2026
COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Clariane annonce l’offre de 500 millions d’euros d’obligations senior en vue de refinancer une partie de son endettement existant
07/09/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Clariane has launched a proposed offering of €500 million of senior notes to refinance part of its existing indebtedness
07/09/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Teva Announces Launch of Offering of Senior Notes
07/09/2026
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue senior notes through its special purpose finance [...]
Virbac : Déclaration d'actions et de droits de vote 07/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 07/2026
07/09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 08/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 08/2026
07/09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases
07/09/2026
ZHUHAI, China, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Rezubio today announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA and Chinese NMPA [...]
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
06/09/2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today [...]
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
06/09/2026
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary [...]
Conavi Medical Announces Media and Digital Marketing Agreements
05/09/2026
TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing [...]
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
05/09/2026
Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 , at the Encore Boston Harbor, as previously reported [...]
The International Myeloma Foundation Mourns the Passing of Former IMF Board Member Dr. Robert A. Kyle — The Father of Multiple Myeloma
05/09/2026
STUDIO CITY, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares news of the passing of Dr. Robert A. Kyle at age 98 — the Father of Myeloma and a [...]

Pages